You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The University of Groningen-led team further uncovered variants associated with risk of dilated cardiomyopathy.
In Science this week: chromatin accessibility of microglia during fetal development, and more.
In Nature this week: watching TV may be a risk factor for coronary artery disease, genomes of five cotton species, and more.
In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.
The team used this system to perform orthogonal and multiplexed genome engineering of endogenous targets using up to 25 individual CRISPR RNAs.
With RNA sequence data on thousands of individual lung cells, researchers fleshed out new and known cell clusters, before digging into cell state and cellular interaction changes in asthma.
In PLOS this week: microRNAs linked to brain metastasis risk in lung cancer, effects of Crohn's disease-linked mutation, and more.
In Science this week: single-cell tools named Breakthrough of the Year winner, differences in gut microbiome composition and function in people with bowel disease, and more.
Research suggests gut microbe representation, abundance, and function may provide clues for diagnosing Crohn's disease, ulcerative colitis, and irritable bowel syndrome.
With genome-wide association studies involving more than 200,000 individuals, researchers narrowed in on 58 loci and dozens of genes with ties to a chronic infection marker.
The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.
According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.